Longgang Cui
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients.
Journal: Translational lung cancer research
Published: November 23, 2021
Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.
Journal: International journal of cancer
Published: November 19, 2021
Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer.
Journal: Frontiers in oncology
Published: August 27, 2021
Comparing Immunotherapies in Combination With Chemotherapy for Previously Untreated Advanced Nonsquamous NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 18, 2020
Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan-cancer analysis.
Journal: Molecular genetics & genomic medicine
Published: July 07, 2020
Efficacy and safety of PD-1/PD-L1 inhibitors plus nab-paclitaxel for patients with non-small cell lung cancer who have progressed after platinum-based chemotherapy.
Journal: Therapeutic advances in medical oncology
Published: January 15, 2020
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Journal: JAMA oncology
Published: December 27, 2019
PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 30, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026